Figure 2

Correlation between IL-6 mRNA expression and clinical parameters (panel a) and effects of Sivelestat or PMX-treatment on MUC1 mRNA (panel b). (a) (left) (a) Kaplan-Meier plot for two conditions (IL-6 mRNA during operation is classified as categorized more or less than 5900) associated with the clinical course of the patients. If the IL-6 mRNA was downregulated to < 5900, the cumulative proportion had a tendency to increase (p = 0.0505), resulting in a shorter period of ventilator dependence. Solid line and dotted line refer to < 5900 and > 5900, respectively. (right) If IL-6 mRNA was downregulated to < 5900, the cumulative proportion was improved significantly (p = 0.0062), resulting in a shorter ICU stay. (b) To describe the therapeutic effects of gene expression on prognosis, the effect on MUC1 mRNA of treatment with sivelestat- (left) or a polymyxin B-immobilized fiber column (PMX) (right) are depicted. Dotted line and solid line refer to sivelestat-treated (n = 13) and untreated (n = 14) patients, respectively. In both cases, the mean value of MUC1 mRNA expression relative to β-action mRNA is shown. (left) Sivelestat caused a significant change in the genes of interest (Table 5). However, it had no significant influence on prognosis (recovery from SIRS). *: p < 0.05, N.S.: not significant. (right) Clinical courses in two PMX-treated cases (#9: solid line and #11: dotted line) are shown. There were no significant relationships between any of the genes and the therapeutic modalities required. Relative MUC1 mRNA expression compared with β-actin mRNA is plotted.